Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
U.S. Congress. House. To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as orphan drugs). H.R. 7640. 117th Cong., 2nd sess., Introduced in House May 3, 2022. https://www.govinfo.gov/app/details/BILLS-117hr7640ih.
Congress, House of Representatives (2022, May 3). To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as orphan drugs). (H.R. 7640 (IH)). Retrieved from https://www.govinfo.gov/app/details/BILLS-117hr7640ih.
United States, Congress, House of Representatives. To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as orphan drugs). U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-117hr7640ih. 117th Congress, H.R. 7640, Introduced in House 3 May. 2022.
H.R.7640 - 117th Congress (2021-2022): To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as orphan drugs)., H.R.7640, 117th Cong. (2022), https://www.govinfo.gov/app/details/BILLS-117hr7640ih.